D. R. A. Uges

1.4k total citations
23 papers, 1.1k citations indexed

About

D. R. A. Uges is a scholar working on Oncology, Molecular Biology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, D. R. A. Uges has authored 23 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 5 papers in Molecular Biology and 4 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in D. R. A. Uges's work include Drug Transport and Resistance Mechanisms (3 papers), Cancer Treatment and Pharmacology (3 papers) and Pharmacological Effects and Toxicity Studies (3 papers). D. R. A. Uges is often cited by papers focused on Drug Transport and Resistance Mechanisms (3 papers), Cancer Treatment and Pharmacology (3 papers) and Pharmacological Effects and Toxicity Studies (3 papers). D. R. A. Uges collaborates with scholars based in Netherlands, United States and Belgium. D. R. A. Uges's co-authors include Dirk Jan Wever, J. de Vries, H.J. Busscher, Albert G. Veldhuizen, Jim R. van Horn, Elisabeth G.E. de Vries, B. E. Smink, J.J. de Gier, Toine C. G. Egberts and Klaas J. Lusthof and has published in prestigious journals such as Journal of Clinical Oncology, Biomaterials and Antimicrobial Agents and Chemotherapy.

In The Last Decade

D. R. A. Uges

23 papers receiving 1.1k citations

Peers

Countries citing papers authored by D. R. A. Uges

Since Specialization

Citations

This map shows the geographic impact of D. R. A. Uges's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. R. A. Uges with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. R. A. Uges more than expected).

Fields of papers citing papers by D. R. A. Uges

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. R. A. Uges. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. R. A. Uges. The network helps show where D. R. A. Uges may publish in the future.

Co-authorship network of co-authors of D. R. A. Uges

This figure shows the co-authorship network connecting the top 25 collaborators of D. R. A. Uges. A scholar is included among the top collaborators of D. R. A. Uges based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. R. A. Uges. D. R. A. Uges is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors 2015 ·Annals of Oncology ·Hink Boer, Johannes H. Proost, Janine Nuver, (unknown), (unknown), (unknown), (unknown), Renske Altena, (unknown), Sjoukje F. Oosting, Judith M. Vonk, Joop D. Lefrandt, D. R. A. Uges, Coby Meijer, Elisabeth G.E. de Vries, Jourik A. Gietema	58
2	Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience 2011 ·European Respiratory Journal ·Arianna D. Pranger, Richard van Altena, Rob E. Aarnoutse, Dick van Soolingen, D. R. A. Uges, Jos G. W. Kosterink, Tjip S. van der Werf, Jan‐Willem C. Alffenaar	51
3	Dried Blood Spots: A New Tool for Tuberculosis Treatment Optimization 2011 ·Current Pharmaceutical Design ·Dinh Hoa Vu, Jan‐Willem C. Alffenaar, Peter M. Edelbroek, J. R. B. J. Brouwers, D. R. A. Uges	60
4	Intravenous Voriconazole after Toxic Oral Administration 2010 ·Antimicrobial Agents and Chemotherapy ·Jan‐Willem C. Alffenaar, Sander van Assen, Jan G.R. de Monchy, D. R. A. Uges, Jos G. W. Kosterink, Tjip S. van der Werf	8
5	Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: A safe combination 2006 ·European Journal of Cancer ·Ronald Hoekstra, Filip De Vos, Ferry A.L.M. Eskens, Elisabeth G.E. de Vries, D. R. A. Uges, Raymond A. Knight, Robert Carr, Rod Humerickhouse, Jaap Verweij, Jourik A. Gietema	38
6	A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors 2006 ·Annals of Oncology ·Jourik A. Gietema, Ronald Hoekstra, Filip De Vos, D. R. A. Uges, Ate van der Gaast, Harry J.M. Groen, Walter J. Loos, Raymond A. Knight, Robert Carr, Rod Humerickhouse, Ferry A.L.M. Eskens	39
7	202 POSTER Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase 1 study in patients with advanced solid malignacies 2006 ·European Journal of Cancer Supplements ·Constantijne H. Mom, Stefan Sleijfer, Jourik A. Gietema, N. L. Fox, (unknown), Larry Lo, D. R. A. Uges, Walter J. Loos, (unknown), Jaco J. Verweij	14
8	Drug use and the severity of a traffic accident 2005 ·Accident Analysis & Prevention ·B. E. Smink, (unknown), Klaas J. Lusthof, J.J. de Gier, D. R. A. Uges, Toine C. G. Egberts	53
9	Quantitative analysis of 33 benzodiazepines, metabolites and benzodiazepine-like substances in whole blood by liquid chromatography?(tandem) mass spectrometry 2004 ·Journal of Chromatography B ·B. E. Smink, (unknown), (unknown), Klaas J. Lusthof, J.J. de Gier, Toine C. G. Egberts, D. R. A. Uges	83
10	Influence of functional polymorphisms of the gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia 2004 ·Clinical Pharmacology & Therapeutics ·Sabine Plasschaert, (unknown), Marike Boezen, Ido P. Kema, Elisabeth G.E. de Vries, D. R. A. Uges, A. Veerman, Willem A. Kamps, Edo Vellenga, (unknown)	73
11	Tremor in the newborn infant caused by maternal smoking. 2002 ·Therapeutic Drug Monitoring ·(unknown), D. R. A. Uges	1
12	The clinical relevance of routine genotyping of CYP2D6/2C19 null alleles of psychiatric patients 2002 ·British Journal of Clinical Pharmacology ·Emmely M. de Vries, (unknown), (unknown), D. R. A. Uges	4
13	A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours 2000 ·British Journal of Cancer ·Robert Paridaens, D. R. A. Uges, (unknown), Leslie Choi, (unknown), Winette T.A. van der Graaf, Harry J.M. Groen, Herlinde Dumez, (unknown), Frits A.J. Muskiet, Renaud Capdeville, A.T. van Oosterom, Elisabeth G.E. de Vries	31
14	Electrochemical and surface characterization of a nickel–titanium alloy 1998 ·Biomaterials ·Dirk Jan Wever, Albert G. Veldhuizen, J. de Vries, H.J. Busscher, D. R. A. Uges, Jim R. van Horn	365
15	Conversion of the prodrug etoposide phosphate to etoposide in gastric juice and bile 1997 ·British Journal of Cancer ·(unknown), (unknown), D. R. A. Uges, NH Mulder, Elisabeth G.E. de Vries	15
16	Pharmacokinetics of Cyclosporine A After Intravenous and Oral Administration in Liver Transplant Patients Measured with High-Performance Liquid Chromatography 1993 ·Therapeutic Drug Monitoring ·I. J. Klompmaker, J. Mark K. H. Wierda, (unknown), D. R. A. Uges, E. B. Haagsma, R. Verwer, M. J. H. Slooff	10
17	A study of human small‐cell lung carcinoma (hsclc) cell lines with different sensitivities to detect relevant mechanisms of cisplatin (cddp) resistance 1990 ·International Journal of Cancer ·Geke A.P. Hospers, (unknown), (unknown), D. R. A. Uges, N. H. Mulder, Elisabeth G.E. de Vries	36
18	High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors. 1989 ·PubMed ·(unknown), D.Th. Sleijfer, P.H.B. Willemse, Elisabeth G.E. de Vries, D. R. A. Uges, N. H. Mulder	46
19	Impairment of organ function after oral ingestion of refined petrol 1988 ·Intensive Care Medicine ·Stefan Janssen, Sjaak van der Geest, S. Meijer, D. R. A. Uges	11
20	Plasma or serum in therapeutic drug monitoring and clinical toxicology 1988 ·Pharmacy World & Science ·D. R. A. Uges	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact